Insulin signal transduction pathway is secreted after glucose enters the beta cell and that triggers several other processes in a chain reaction. While insulin is secreted by the pancreas to lower blood glucose levels, glucagon is secreted to raise blood glucose levels. This is why glucagon has been known for decades as a counter-regulatory hormone. When blood glucose levels are low, the pancreas secretes glucagon, which in turn causes the liver to convert stored glycogen polymers into glucose monomers, which is then released into the blood. This process is called glycogenolysis. Liver cells, or hepatocytes, have glucagon receptors which allow for glucagon to attach
Braasch Biotech intellectual property positions by multiple filings and anticipates several additional filings to support their technology. Somatostatin (also known as Growth Hormone Inhibiting Hormone) is the main regulator for the release of Growth Hormone (GH) from the pituitary gland, which leads to several body functions including an increase of IGF-1 (Insulin-like Growth Factor 1) levels. Somatostatin inhibits the actions of Growth Hormone-Releasing Hormone, also a hypothalamus hormone, which controls the release of Growth Hormone. Braasch's Somatostatin vaccine technology allows the immune system to temporarily reduce, but not completely eliminate, the mostly inhibitory actions of Somatostatin. The vaccination effect causes more Growth